Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22650704 | 0.77 | PIK3CA (0.36) | PDE3BPDE3AHTR1DCDC7CDK2 | |
| SCHEMBL31394806 | 0.73 | IRAK4 (0.46) | IRAK4 | |
| SCHEMBL31387118 | 0.72 | IRAK4 (0.43) | IRAK4 | |
| SCHEMBL30483016 | 0.72 | LPL (0.49) | IRAK4 | |
| SCHEMBL16610635 | 0.70 | MAPK1 (0.57) | MAPK1HTR1D | |
| SCHEMBL22650739 | 0.70 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL22551943 | 0.70 | IRAK4 (0.41) | IRAK4 | |
| SCHEMBL23484478 | 0.70 | MAPK1 (0.50) | MAPK1HTR1D | |
| SCHEMBL22650904 | 0.70 | IRAK4 (0.39) | IRAK4 | |
| SCHEMBL30748763 | 0.70 | MAPK1 (0.53) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | MAPK1 148/4885IRAK4 2748/4885PDE3B 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.